Cargando…

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS

OBJECTIVE: To assess the relationship between CD56(bright) natural killer (NK) cells and multiple sclerosis (MS) disease activity in patients with relapsing-remitting MS treated with daclizumab high-yield process (DAC HYP). METHODS: Data were from patients enrolled in a 52-week randomized, double-bl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elkins, J., Sheridan, J., Amaravadi, L., Riester, K., Selmaj, K., Bielekova, B., Parr, E., Giovannoni, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309527/ https://www.ncbi.nlm.nih.gov/pubmed/25635261 http://dx.doi.org/10.1212/NXI.0000000000000065

Ejemplares similares

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2016)

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
por: Benedict, Ralph HB, et al.
Publicado: (2017)

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
por: Tran, Jonathan Q, et al.
Publicado: (2016)

Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
por: Reardon, Jennifer, et al.
Publicado: (2013)

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2020)

Pharmacodynamic effects of daclizumab in the intrathecal compartment
por: Komori, Mika, et al.
Publicado: (2017)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination
por: Lin, Yen Chih, et al.
Publicado: (2016)

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
por: Lin, Yen Chih, et al.
Publicado: (2015)

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
por: Krueger, James G., et al.
Publicado: (2016)

Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry
por: Ranganath, Thanmayi, et al.
Publicado: (2020)

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program
por: Gold, Ralf, et al.
Publicado: (2016)

Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients
por: Rommer, Paulus S., et al.
Publicado: (2020)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer Cells
por: Schwane, Vera, et al.
Publicado: (2020)

Evaluation of CD56(dim) and CD56(bright) natural killer cells in peripheral blood of women with IVF failures
por: Mardanian, Farahnaz, et al.
Publicado: (2015)

Human Circulating and Tissue-Resident CD56(bright) Natural Killer Cell Populations
por: Melsen, Janine E., et al.
Publicado: (2016)

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS
por: Luessi, Felix, et al.
Publicado: (2018)

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
por: Cohan, Stanley, et al.
Publicado: (2017)

Human Natural Killer Cell Maturation Defect Supports In Vivo CD56(bright) to CD56(dim) Lineage Development
por: Domaica, Carolina Inés, et al.
Publicado: (2012)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Intratumoral CD56(bright) natural killer cells are associated with improved survival in bladder cancer
por: Mukherjee, Neelam, et al.
Publicado: (2018)

CD56(bright) natural killer cells preferentially kill proliferating CD4(+) T cells
por: Lee, Mercede, et al.
Publicado: (2023)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Pilot study of a ketogenic diet in relapsing-remitting MS
por: Brenton, J. Nicholas, et al.
Publicado: (2019)

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
por: Nash, Richard A., et al.
Publicado: (2017)

Hobit expression by a subset of human liver-resident CD56(bright) Natural Killer cells
por: Lunemann, Sebastian, et al.
Publicado: (2017)

CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis
por: Laroni, Alice, et al.
Publicado: (2020)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Cost Effectiveness Analysis of Avonex and CinnoVex in Relapsing Remitting MS
por: Najafi, Behzad, et al.
Publicado: (2015)

Neurofilament light chain predicts disease activity in relapsing-remitting MS
por: Varhaug, Kristin N., et al.
Publicado: (2017)

Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)
por: Camu, William, et al.
Publicado: (2019)

Cytotoxicity of Human Hepatic Intrasinusoidal CD56(bright) Natural Killer Cells against Hepatocellular Carcinoma Cells
por: Hwang, Shin, et al.
Publicado: (2019)

Complex formation constant of ferric ion with Gly, Pro-Hyp and Gly-Pro-Hyp
por: Zhi, Mingyu, et al.
Publicado: (2018)

A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy
por: Wuest, Simone C., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7rb2qjkbdpe9v55em9lpca4osh